This company has been marked as potentially delisted and may not be actively trading. Blue Water Acquisition (BLUW) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock BLUW vs. IKT, PLX, IZTC, CRTX, CVM, ZIVO, JATT, CLDI, FNCH, and ALVRShould you be buying Blue Water Acquisition stock or one of its competitors? The main competitors of Blue Water Acquisition include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Cortexyme (CRTX), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), JATT Acquisition (JATT), Calidi Biotherapeutics (CLDI), Finch Therapeutics Group (FNCH), and AlloVir (ALVR). These companies are all part of the "medical" sector. Blue Water Acquisition vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Cortexyme CEL-SCI ZIVO Bioscience JATT Acquisition Calidi Biotherapeutics Finch Therapeutics Group AlloVir Inhibikase Therapeutics (NYSE:IKT) and Blue Water Acquisition (NASDAQ:BLUW) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Do insiders & institutionals have more ownership in IKT or BLUW? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 70.1% of Blue Water Acquisition shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, IKT or BLUW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.57Blue Water AcquisitionN/AN/A-$4.72MN/AN/A Do analysts prefer IKT or BLUW? Inhibikase Therapeutics presently has a consensus price target of $6.50, indicating a potential upside of 327.63%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than Blue Water Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Blue Water Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IKT or BLUW more profitable? Blue Water Acquisition's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Blue Water Acquisition N/A N/A N/A Does the media prefer IKT or BLUW? In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 1 articles in the media. Inhibikase Therapeutics' average media sentiment score of 0.00 equaled Blue Water Acquisition'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Blue Water Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInhibikase Therapeutics and Blue Water Acquisition tied by winning 4 of the 8 factors compared between the two stocks. Get Blue Water Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLUW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUW vs. The Competition Export to ExcelMetricBlue Water AcquisitionBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.13M$269.83M$5.52B$9.34BDividend YieldN/AN/A4.74%4.13%P/E RatioN/AN/A28.9823.78Price / SalesN/A327.48450.22179.75Price / CashN/A22.4424.4827.20Price / Book4.2510.418.345.61Net Income-$4.72M-$106.40M$3.25B$265.26M Blue Water Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUWBlue Water AcquisitionN/A$9.980.0%N/A+3.6%$72.13MN/A0.002IKTInhibikase Therapeutics1.6681 of 5 stars$1.65-2.9%$6.50+293.9%+14.3%$122.66MN/A-0.626PLXProtalix BioTherapeutics2.4014 of 5 stars$1.49+2.1%$15.00+906.7%+38.1%$118.61M$59.76M-11.46200IZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpCRTXCortexymeN/A$1.85-0.5%N/A+140.0%$55.78MN/A-0.6255CVMCEL-SCI1.1181 of 5 stars$8.58+20.0%N/A-72.6%$45.65MN/A-17.8743News CoveragePositive NewsShort Interest ↑High Trading VolumeZIVOZIVO BioscienceN/A$10.70flatN/A+17.3%$40.84M$15.85K-2.1910High Trading VolumeJATTJATT AcquisitionN/A$1.47-9.3%N/A-58.8%$25.36MN/A0.003Gap DownHigh Trading VolumeCLDICalidi Biotherapeutics0.2993 of 5 stars$0.59-7.4%N/A-61.4%$21.25MN/A0.0038Short Interest ↑Gap DownFNCHFinch Therapeutics GroupN/A$12.50flatN/A+523.5%$20.08MN/A-1.42190Gap DownALVRAlloVirN/A$2.69-8.0%N/A-84.8%$13.57MN/A-0.13110Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies IKT Competitors PLX Competitors IZTC Competitors CRTX Competitors CVM Competitors ZIVO Competitors JATT Competitors CLDI Competitors FNCH Competitors ALVR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLUW) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blue Water Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blue Water Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLUW Stock Alerts